

Hemovigilance Module Adverse Reaction Acute Hemolytic Transfusion Reaction

*Required for saving					
*Facility ID#: NHSN Ac	lverse Reaction #:				
Patient Information					
*Patient ID:	*Gender: 🗌 M 🗌 F 🗌 Other *Date of Birth://				
Social Security #:	Secondary ID: Medicare #:				
Last Name:	First Name: Middle Name:				
Ethnicity 🗌 Hispanic or Latino	Not Hispanic or Not Latino				
Race 🗌 American Indian/Alaska Native 🗌 Asian 🔄 Black or African American					
🗌 Native Hawaiian/Othe	er Pacific Islander 🛛 🗌 White				
*Blood Group: 🗌 A- 🗌 A+ 🗌 E	B- □B+ □ AB- □ AB+ □ O- □ O+ □ Blood type not done				
🗌 Transitional ABO / I	Rh + 🔄 Transitional ABO / Rh - 🔄 Transitional ABO / Transitional Rh				
Group A/Transitional Rh	B/Transitional Rh 🔲 Group O/Transitional Rh 🔄 Group AB/Transitional Rh				
Patient Medical History					
List the patient's admitting diagnos	sis. (Use ICD-10 Diagnostic codes/descriptions)				
Code:	Description:				
Code:	Description:				
	Description:				
	tion for transfusion. (Use ICD-10 Diagnostic codes/descriptions)				
Code:	Description:				
Code:	Description:				
	Description:				
List the patient's comorbid condition reaction. <i>(Use ICD-10 Diagnostic condition)</i>	ons at the time of the transfusion related to the adverseUNKNOWNcodes/descriptions)NONE				
Code:	Description:				
Code:	Description:				
	Description:				
of any individual or institution is collected w stated, and will not otherwise be disclosed	ly provided information obtained in this surveillance system that would permit identification ith a guarantee that it will be held in strict confidence, will be used only for the purposes or released without the consent of the individual, or the institution in accordance with Health Service Act (42 USC 242b, 242k, and 242m(d)).				
reviewing instructions, searching existing d collection of information. An agency may n	information is estimated to average 20 minutes per response, including the time for ata sources, gathering and maintaining the data needed, and completing and reviewing the ot conduct or sponsor, and a person is not required to respond to a collection of information itrol number. Send comments regarding this burden estimate or any other aspect of this				

Atlanta, GA 30333 ATTN: PRA (0920-0666).

collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74,



	dical procedure including past procedures and procedures to be UNKNOWN hospital or outpatient stay. (Use ICD-10 Procedure NONE				
Code:	Description:				
Code:	Description:				
Code:	Description:				
Additional Information					
Transfusion History					
Has the patient received a pr	evious transfusion?				
Blood Product:	VB 🗌 RBC 🔲 Platelet 🗌 Plasma 🔲 Cryoprecipitate 🗌 Granulocyte				
Date of Transfusion:					
Was the patient's adverse	reaction transfusion-related?				
	about the transfusion adverse reaction.				
	e reaction: Allergic AHTR DHTR DSTR FNHTR				
] PTP TACO TAD TA-GVHD TRALI UNKNOWN				
Reaction Details					
	/ *Time reaction occurred::				
*Facility location where patier					
Is this reaction associated with a	an incident? Yes No If Yes, Incident #:				
Investigation Results					
* Acute hemolytic transfus					
	Non-immune (specify)				
*Case Definition					
	ccurred during, or within 24 hours of cessation of transfusion with <i>new</i> onset:				
	Chills/rigors Epistaxis Disseminated intravascular coagulation (DIC)				
	☐ Hypotension ☐ Fever ☐ Hematuria (gross visual hemolysis)				
☐ Pain and/or oozing at I	V site Renal failure				
Check all that apply:	Decreased fibrinogen 🛛 Decreased haptoglobin 🗌 Elevated bilirubin				
Elevated LDH	moglobinemia 🔲 Hemoglobinuria 🗌 Plasma discoloration c/w hemolysis				
☐ Spherocytes on blood film ☐ Positive direct antiglobulin test (DAT) for anti-IgG or anti-C3					
Positive elution test with alloantibody present on the transfused red blood cells					
Serologic testing is negative, and physical cause (e.g., thermal, osmotic, mechanical, chemical) is confirmed.					
🗌 Physical cause is exclu	ided but serologic evidence is not sufficient to meet definitive criteria.				
Physical cause is suspected and serologic testing is negative.					
AHTR is suspected, bu	t symptoms, test results, and/or information are not sufficient to confirm reaction.				
Other signs and symptoms: (<u>check all that apply)</u>				
Generalized:	□ Nausea/vomiting				
Cardiovascular:	Shock				



Form Approved OMB No. 0920-0666 Exp. Date: 01/31/25 www.cdc.gov/nhsn

					inini.ede.get/inien		
Cutaneous:	🗌 Edema	Flushing		🗌 Jaur	ndice		
	Other rash	🗌 Pruritus ((itching)	Urtic	aria (hives)		
Hemolysis/Hemorrhage:	🗌 Hemoglobinemia	Positive a	antibody scree	n			
Pain:	Abdominal pain						
Poppiratory:	Bilateral infiltrates on	chest x-ray [🗌 Bronchospa	ısm [Cough		
Respiratory:	Shortness of breath	[🗌 Hypoxemia				
Other: (specify)							
*Severity							
Did the patient receive or ex	perience any of the follow	/ing?					
No treatment require	ed 🗌	Symptomatic	treatment only	/			
Hospitalization, inlcu	uding prolonged hospitaliz				g reaction		
Disability and/or inca	apacitation	Congenital ar	nomaly or birth	defect(s	s) of the fetus		
☐ Other medically imp	ortant conditions	Death	Unkno	wn or no	ot stated		
*Imputability							
Which best describes the rel	ationship between the tra	nsfusion and t	he reaction?				
ABO or other allotypic	RBC antigen incompatibi	lity is known.					
Only transfusion-relate	ed (i.e., immune or non-im	imune) cause	of acute hemo	lysis is p	resent.		
•	tial causes present that co	ould explain ac	oute hemolysis	, but tran	sfusion is the most		
likely cause.							
	hemolysis are more likely						
	favor of a cause other than						
	There is conclusive evidence beyond reasonable doubt of a cause other than the transfusion.						
I he relationship between the second seco	een the adverse reaction a	and the transfu	ision is unknov	vn or not	i stated.		
Did the transfusion occur at	your facility?	ES 🗌 NO					
Module-generated Design							
NOTE: Designations for case de application based on responses					d in the NHSN		
*Do you agree with the <u>ca</u>	<u>ase definition</u> designatio	n?	🗌 Y	′ES	🗌 NO		
Please indicate your designation	gnation						
*Do you agree with the <u>se</u>	everity designation?		□ Y	′ES	□ NO		
Please indicate your designation	gnation						
* Do you agree with the <u>in</u> ^Please indicate your desig			□ Y	′ES	□ NO		
Patient Treatment							
			YES [
Did the patient receive treatment (a):	ient for the transfusion rea	action ?					
If yes, select treatment(s):	e type of medication)						
Medication (Select the type of medication) Antipyretics Antihistamines Inotropes/Vasopressors Bronchodilator Diuretics							
Intravenous Immunoglobulin Intravenous steroids Corticosteroids Antibiotics							
Antibiolics							
Volume resuscitation (Intravenous colloids or crystalloids)							



NATIONAL HE, SAFETY NE					Exp	Form App 3 No. 0920 5. Date: 01 ww.cdc.gov)-0666 /31/25			
 Respiratory support (Select the type of support) Mechanical ventilation Noninvasive ventilation Oxygen 										
 Renal replacement therapy (Select the type of therapy) Hemodialysis Peritoneal Continuous Veno-Venous Hemofiltration 										
Phlebotomy Other Specify:										
Outcome										
*Outcome: Death Major or long-term sequelae Minor or no sequelae Not determined Date of Death: // ^If recipient died, relationship of transfusion to death: Definite Probable Possible Doubtful Ruled Out Not determined Cause of death: Was an autopsy performed? Yes No										
Component	Dotails									
Component Details *Was a particular unit implicated in (i.e., responsible for) the adverse reaction?] N/A	
Transfusion Start and End Date/Time	*Component code (check system used)	Amount transfused at reaction onset	(Requ	Jnit number equired for ection and*Unit expiration*Blood groupALI)Date/Timeof unit			р	Implic ated Unit?		
^IMPLICATED	UNIT									
/	□ ISBT-128									
:	Codabar	☐ Entire unit ☐ Partial unit mL			//	□ A- □B+	□ A+	□ в- □ ав+	Y	
·						0-		□ N/A		
; //	 □ ISBT-128			· <u></u>	··					
:	🗌 Codabar	☐ Entire unit ☐ Partial unit mL			//	□ A-	□ A+	□ в-	Ν	
·//	·			·		□B+ □ 0-	□ AB- □ O+	□ AB+ □ N/A		
Custom Fields										
Label				Label						
		//	_				_/	/		
Comments										